TY - JOUR
T1 - A model of the economic benefits of global hepatitis C elimination
T2 - an investment case
AU - Scott, Nick
AU - Kuschel, Christian
AU - Pedrana, Alisa
AU - Schroeder, Sophia
AU - Howell, Jessica
AU - Thompson, Alexander
AU - Wilson, David P.
AU - Hellard, Margaret
N1 - Funding Information:
We are grateful to Yvan Hutin and Gottfried Hirnschall for useful discussions on the analysis. The authors gratefully acknowledge the support to the Burnet Institute provided by the Victorian Government Operational Infrastructure Support Program. AP, JH, and MH are the recipients of National Health and Medical Research Council fellowships. This work received funding from the Qatar Foundation as part of their support for the World Innovations Summit for Health, 2018. The funders had no role in the decision to publish or in the preparation of the manuscript.
Funding Information:
We are grateful to Yvan Hutin and Gottfried Hirnschall for useful discussions on the analysis. The authors gratefully acknowledge the support to the Burnet Institute provided by the Victorian Government Operational Infrastructure Support Program. AP, JH, and MH are the recipients of National Health and Medical Research Council fellowships. This work received funding from the Qatar Foundation as part of their support for the World Innovations Summit for Health, 2018. The funders had no role in the decision to publish or in the preparation of the manuscript.
Funding Information:
The Qatar Foundation provided funding for the initial World Innovations Summit for Health report to the Burnet Institute. NS receives investigator-initiated research funding from Gilead Sciences unrelated to this work. AP has received investigator-initiated research funding from Gilead Sciences, AbbVie, and Merck, and honoraria from Gilead Sciences. JH received the Gilead Sciences Australia fellowship (2017) and honoraria from Gilead Sciences. AT has received investigator-initiated research funding from Gilead Sciences, AbbVie, and Merck; is an advisory board member for Gilead Sciences, AbbVie, Merck, BMS, Bayer, and Eisai; and is a speaker for Gilead Sciences, Abbvie, Merck, Bayer and BMS. MH and the Burnet Institute receive investigator-initiated research funding from Gilead Sciences, AbbVie, and BMS unrelated to this work. CK, SS, and DPW declare no competing interests.
Publisher Copyright:
© 2020 Elsevier Ltd
PY - 2020/10
Y1 - 2020/10
N2 - Major gains in reducing the burden of hepatitis C are now possible because of the discovery of a cure. The prevention of premature deaths and increased workforce participation among people who are cured are likely to provide substantial indirect economic benefits. We developed an investment case for hepatitis C for the six WHO world regions, which, to our knowledge, is the first to consider both indirect and direct economic benefits in this context. Scaling up of testing and treatment to reach the 2030 WHO hepatitis C elimination targets was estimated to prevent 2·1 million (95% credible interval 1·3–3·2 million) hepatitis C-related deaths and 10 million (4–14 million) new hepatitis C virus infections globally between 2018 and 2030. This elimination strategy was estimated to cost US$41·5 billion (33·1–48·7 billion) in testing, treatment, and health care between 2018 and 2030 ($23·4 billion more than the status quo scenario of no testing or treatment scale up), with a global average of $885 (654–1189) per disability-adjusted life-year averted at 2030. Compared with the status quo scenario, the elimination scenario generated $46·1 billion (35·9–53·8 billion) in cumulative productivity gains by 2030. These indirect costs made elimination cost-saving by 2027, with a net economic benefit of $22·7 billion (17·1–27·9 billion) by 2030. This model shows that countries might be underestimating the true burden of hepatitis C and will benefit from investing in elimination.
AB - Major gains in reducing the burden of hepatitis C are now possible because of the discovery of a cure. The prevention of premature deaths and increased workforce participation among people who are cured are likely to provide substantial indirect economic benefits. We developed an investment case for hepatitis C for the six WHO world regions, which, to our knowledge, is the first to consider both indirect and direct economic benefits in this context. Scaling up of testing and treatment to reach the 2030 WHO hepatitis C elimination targets was estimated to prevent 2·1 million (95% credible interval 1·3–3·2 million) hepatitis C-related deaths and 10 million (4–14 million) new hepatitis C virus infections globally between 2018 and 2030. This elimination strategy was estimated to cost US$41·5 billion (33·1–48·7 billion) in testing, treatment, and health care between 2018 and 2030 ($23·4 billion more than the status quo scenario of no testing or treatment scale up), with a global average of $885 (654–1189) per disability-adjusted life-year averted at 2030. Compared with the status quo scenario, the elimination scenario generated $46·1 billion (35·9–53·8 billion) in cumulative productivity gains by 2030. These indirect costs made elimination cost-saving by 2027, with a net economic benefit of $22·7 billion (17·1–27·9 billion) by 2030. This model shows that countries might be underestimating the true burden of hepatitis C and will benefit from investing in elimination.
UR - https://www.scopus.com/pages/publications/85089362904
U2 - 10.1016/S2468-1253(20)30008-X
DO - 10.1016/S2468-1253(20)30008-X
M3 - Review Article
C2 - 32730785
AN - SCOPUS:85089362904
SN - 2468-1253
VL - 5
SP - 940
EP - 947
JO - The Lancet Gastroenterology & Hepatology
JF - The Lancet Gastroenterology & Hepatology
IS - 10
ER -
SDG 3 Good Health and Well-being